Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7413714 | 0.92 | ITGB3 (0.80) | ITGB3ITGA2B | |
| SCHEMBL7407564 | 0.92 | ITGB3 (0.80) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL24336949 | 0.91 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL344302 | 0.91 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL919675 | 0.89 | ITGB3 (0.95) | ITGB3ITGA2B | |
| SCHEMBL7214664 | 0.87 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7214752 | 0.87 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7217243 | 0.87 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7409072 | 0.85 | ITGB3 (0.73) | ITGB3ITGA2B | |
| SCHEMBL7213400 | 0.84 | ITGB3 (1.00) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610858-B2 | Antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex; thrombolytic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20020165400-A1 | Efficient method for the conversion of nitriles to amidines | MA PHILIP (US) | 2002-11-07 | — | — | US | disclosed |
| US-6399784-B2 | TREATMENT OF CORRESPONDING NITRILE DERIVATIVE WITH HYDROGEN IN THE PRESENCE OF HYDROGENATION CATALYST; THROMBOLYTIC AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-04 | — | — | US | disclosed |
| US-20010008886-A1 | Efficient method for the conversion of nitriles to amidines | MA PHILIP (US) | 2001-07-19 | — | — | US | disclosed |
| US-6245914-B1 | HYDROGENATION; THROMBOLYIC AGENTS; ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2001-06-12 | — | — | US | disclosed |
| EP-1023274-A1 | AN EFFICIENT METHOD FOR THE CONVERSION OF NITRILES TO AMIDINES | Du Pont Pharmaceuticals Company (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999018090-A1 | AN EFFICIENT METHOD FOR THE CONVERSION OF NITRILES TO AMIDINES | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008886-A1 | Efficient method for the conversion of nitriles to amidines | FGB, F13B, TFPI | ITGB3 67/4885ITGA2B 40/4885 |
| US-20020165400-A1 | Efficient method for the conversion of nitriles to amidines | FGB, F13B, TFPI | ITGB3 67/4885ITGA2B 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.